Skip to content

Open-label, prospective, multicenter study to assess efficacy and safety of Lactacol/Lactazak®, a food supplement in intestinal colic and bloating

Open-label, Prospective, multicenter study to Assess effiCacy and safEty of Lactacol/Lactazak®, a food supplement in intestinal colic and bloating

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN17581847
Enrollment
30
Registered
2024-08-26
Start date
2024-01-23
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal colic and bloating Digestive System

Interventions

This non-interventional study is conducted in Bulgaria in routine clinical practice by GPs. Data is to be collected prospectively. Lactacol/Lactazak® will be administered in accordance with the approv

Sponsors

Pharmunion LLC
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pediatric population 0-4 months 2. Established diagnosis: FGIDs (intestinal colic and bloating) 3. Signed Informed Consent for data collecting

Exclusion criteria

Exclusion criteria: 1. Unwillingness to provide signed Informed Consent for data collecting 2. Patients participating in other trials 3. Allergy to any of the product ingredients

Design outcomes

Primary

MeasureTime frame
1. Baby's crying due to colic (number of babies crying episodes during 24 h) measured by reviewing patient’s diary daily 2. Bloating measured using (3-point Likert scale: 1 – None, 2 – Moderate, 3 – Intense) recorded in patient’s diary daily

Secondary

MeasureTime frame
To assess the effectiveness of the product administration by the responses to below questions during the study period: 1. “How many hours in total does your child sleep per 24-h period?” 2. “How many hours in total do you (as caregiver) sleep per 24-h period?” 3. “How often does your child usually wake during the night?” To assess the safety of the product administration in terms of the following: 1. AE occurrence when reported by the caregiver 2. Withdrawals due to lack of tolerability when reported by the caregiver

Countries

Bulgaria

Contacts

Public ContactAlina Iordache
alina.iordache@cebis-int.com+40 (0)737640721

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026